DOCSLIB.ORG

( 12 ) United States Patent

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US009833513B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 ,833 ,513 B2 Larson et al. (45 ) Date of Patent: Dec . 5 , 2017 ( 54 ) LIQUID PROTEIN FORMULATIONS FOR CO7K 16 /241 ( 2013 .01 ) ; CO7K 16 / 2839 INJECTION COMPRISING ( 2013 . 01 ) ; COZK 16 /2863 (2013 .01 ) ; COOK 1 -BUTYL - 3 -METHYLIMIDAZOLIUM 16 / 2887 ( 2013 .01 ) ; CO7K 16 / 32 ( 2013 . 01 ) ; METHANESULFONATE AND USES A61K 38/ 00 ( 2013 .01 ) THEREOF (58 ) Field of Classification Search ( 71 ) Applicant : EAGLE BIOLOGICS , INC ., None Woodcliff Lake, NJ (US ) See application file for complete search history . (72 ) Inventors: Alyssa M . Larson , Dana Point, CA (US ) ; Kevin Love, Boston , MA (US ) ; (56 ) References Cited Alisha K . Weight, Mill Creek , WA (US ) ; Alan Crane , Waban , MA (US ) ; U . S . PATENT DOCUMENTS Robert S . Langer, Newton , MA (US ) ; 3 ,682 , 174 A 8 / 1972 Cohen Alexander M . Klibanov, Boston , MA 4 ,092 ,410 A 5 / 1978 Ogata et al . (US ) 4 ,171 , 698 A 10 / 1979 Genese 5 , 001 ,000 A 3 / 1991 Rohrbacher et al . 5 , 034 ,506 A 7 / 1991 Summerton et al . ( 73 ) Assignee : Eagle Biologics , Inc. , Woodcliff Lake, 5 , 142 ,047 A 8 / 1992 Summerton et al . NJ (US ) 5 , 166 ,315 A 11/ 1992 Summerton et al. 5 ,217 , 866 A 6 / 1993 Summerton et al. ( * ) Notice : Subject to any disclaimer , the term of this 5 ,334 , 162 A 8 / 1994 Harris patent is extended or adjusted under 35 5 , 356 , 802 A 10 / 1994 Chandrasegaran U . S . C . 154 ( b ) by 507 days . 5 ,454 ,786 A 10 / 1995 Harris 5 , 487 , 994 A 1 / 1996 Chandrasegaran (21 ) Appl. No. : 14/ 484 ,053 5 ,506 , 337 A 4 / 1996 Summerton et al. 5 ,521 , 063 A 5 / 1996 Summerton et al . 5 ,527 ,675 A 6 / 1996 Coull (22 ) Filed : Sep . 11, 2014 5 , 539 , 082 A 7 / 1996 Nielsen et al . 5 ,569 , 193 A 10 / 1996 Hofstetter et al . ( 65 ) Prior Publication Data 5 ,608 , 038 A 3 / 1997 Eibl et al . US 2015 / 0071922 A1 Mar . 12, 2015 5 ,623 ,049 A 4 / 1997 Lobberding et al . 5 ,698 ,685 A 12/ 1997 Summerton et al. 5 ,714 ,331 A 2 / 1998 Buchardt et al. Related U . S . Application Data 5 , 736 , 336 A 4 / 1998 Buchardt et al . (60 ) Provisional application No . 62 / 030 , 521, filed on Jul. ( Continued ) 29 , 2014 , provisional application No . 62 /026 ,497 , filed on Jul. 18 , 2014 , provisional application No . FOREIGN PATENT DOCUMENTS 62/ 008, 050 , filed on Jun . 5 , 2014 , provisional application No. 61 / 988 ,005 , filed on May 2 , 2014 , EP 1981824 10 /2008 provisional application No . 61/ 946 ,436 , filed on Feb . EP 2335725 6 / 2011 28 , 2014 , provisional application No . 61/ 943, 197 , (Continued ) filed on Feb . 21, 2014 , provisional application No . 61 / 940 ,227 , filed on Feb . 14 , 2014 , provisional OTHER PUBLICATIONS application No. 61/ 876 ,621 , filed on Sep . 11 , 2013 . Earle and Seddon , “ Ionic liquids green solvents for the future” , (51 ) Int . CI. Pure Appl . Chem ., 72 ( 7 ) : 1391 - 8 ( 2000 ) . A61K 39 /395 ( 2006 .01 ) (Continued ) A61K 47 /06 ( 2006 .01 ) A61K 47 / 24 ( 2006 .01 ) A61K 9 /00 ( 2006 .01 ) Primary Examiner — Yunsoo Kim A61K 47 / 20 ( 2006 . 01 ) ( 74 ) Attorney , Agent, or Firm — Baker & Hostetler LLP A61K 47 / 22 ( 2006 . 01 ) CO7K 16 /22 ( 2006 .01 ) COOK 16 / 24 ( 2006 . 01 ) (57 ) ABSTRACT COZK 16 / 28 ( 2006 . 01 ) A61K 47 / 18 ( 2017 .01 ) Concentrated , low - viscosity , low - volume liquid pharmaceu A61K 9 / 19 ( 2006 .01 ) tical formulations of proteins have been developed . Such CO7K 16 /32 ( 2006 . 01 ) formulations can be rapidly and conveniently administered A61K 38 /00 ( 2006 .01 ) by subcutaneous or intramuscular injection , rather than by (52 ) U . S . CI. lengthy intravenous infusion . These formulations include CPC . .. A61K 47 / 06 ( 2013 .01 ) ; A61K 9 / 0019 low -molecular -weight and / or high -molecular - weight pro (2013 .01 ) ; A61K 9 / 19 (2013 .01 ) ; A61K teins , such as mAbs, and viscosity - reducing ionic liquids. 39 / 3955 ( 2013 .01 ) ; A61K 47/ 186 ( 2013 .01 ) ; A61K 47/ 20 (2013 . 01) ; A61K 47 / 22 (2013 . 01) ; A61K 47 / 24 ( 2013 .01 ) ; C07K 16 / 22 ( 2013 .01 ) ; 26 Claims, No Drawings US 9 ,833 Page, 513 2 B2 (56 ) References Cited 2016 /0074515 Al 3 /2016 Soane et al . 2016 /0090419 Al 3 / 2016 Morichika et al. U . S . PATENT DOCUMENTS 2016 /0193346 A17 / 2016 Houston et al . 2016 /0367675 Al 12 /2016 Liu et al. 5 , 773 ,571 A 6 / 1998 Nielsen et al. 2017 /0049888 AL 2 /2017 Liu et al. 5 , 779 ,668 A 7 / 1998 Grabenkort 5 , 786 , 571 A 7 / 1998 Bethel et al. FOREIGN PATENT DOCUMENTS 5 ,819 , 988 A 10 / 1998 Sawhney et al. 5 . 871, 736 A 2 / 1999 Bruegger et al . EP 2538973 1 / 2013 5 , 962 ,405 A 10 / 1999 Seelich wo W00244321 A2 6 / 2002 6 ,065 ,645 A 5 /2000 Sawhney et al . WO 2004089335 10 / 2004 6 ,171 , 586 B1 1 / 2001 Lam et al . WO 2006071693 7 / 2006 6 , 267 , 958 B1 7 / 2001 Andya et al. WO 2009015367 1 / 2009 6 , 394 , 314 B1 5 / 2002 Sawhney et al . WO 2009026122 2 / 2009 6 , 443 , 612 B1 9 / 2002 Keller Wo 2009043049 4 / 2009 6 , 457 , 609 B1 10 / 2002 Keller WO 2010132047 11 / 2010 6 , 525 , 102 B1 2 / 2003 Chen et al. WO WO2010132047 Al 11 / 2010 6 , 551 , 840 B2 4 / 2003 Ono et al. WO 2011069037 6 / 2011 6 , 564 ,972 B2 5 / 2003 Sawhney et al. WO WO2011072246 A2 6 / 2011 6 , 685 , 940 B2 2 / 2004 Andya et al. WO 2011095543 8 / 2011 6 , 698 , 622 B2 3 / 2004 Sawhney et al. WO 2011109415 9 / 2011 6 , 730 , 328 B2 5 / 2004 Maskiewicz WO 2011139718 11 / 2011 6 , 875 , 432 B2 4 / 2005 Liu WO WO2012010832 A1 1 /2012 7 ,390 , 786 B2 6 / 2008 Warne et al . WO 2012141978 10 / 2012 7 ,501 , 000 B2 3 / 2009 Rosenflanz et al . WO 2013096791 6 / 2013 7 ,666 , 413 B2 2 / 2010 Liu WO WO2013176772 AL 11/ 2013 7 , 740 , 842 B2 6 / 2010 Arvinte wo WO2014018423 A2 1 / 2014 7 , 758, 860 B2 7 / 2010 Warne WO 2014023816 2 / 2014 8 , 142 , 776 B2 3 / 2012 Liu 8 ,383 , 114 B2 2 / 2013 Sloey et al . 8 , 476, 239 B2 7 / 2013 Dali et al. OTHER PUBLICATIONS 8 , 500 , 681 B2 8 / 2013 Gonnelli et al . 8 ,703 , 126 B2 4 / 2014 Liu et al . International Search Report for PCT/ US2014 /055245 dated May 8 , 715 , 651 B2 5 / 2014 Maestro et al. 29 , 2015 . 8 , 779, 094 B2 7 / 2014 Johnston et al . 8 , 802 , 095 B2 8 / 2014 Houston et al . Riduan and Zhang , “ Imidazolium salts and their polymeric mate 8 , 906 , 368 B2 12 / 2014 Bolli et al . rials for biological applications" , Chem . Soc Rev . , 42 :9055 - 70 9 ,072 , 668 B2 7 / 2015 Dai et al. ( 2013 ) . 9 , 084 , 743 B2 7 / 2015 Teschner et al. Sheldon , et al. , “ Biocatalysts in ionic liquids ” , Green Chem ., 9 , 084 , 777 B2 7 / 2015 Morichika et al. 4 : 147 - 51 (2002 ) . 9 , 309, 316 B2 4 / 2016 Dali et al . van Rantwijk and Sheldon , “ Biocatalysis in ionic liquids ” , Chem 9 , 320, 797 B2 4 / 2016 Sloey et al . 9 , 457 , 089 B2 10 / 2016 Soula Rev . , 107 : 2757 -65 (2007 ) . 9 , 605, 051 B2 3 / 2017 Soane et al . Baker , et al ., “ Fluorescence quenching immunoassay performed in 2002 / 0190082 Al 12 / 2002 Keller an ionic liquid ” , Royal Doc Chem ., (27 ) :2851 - 3 (2006 ) . 2003 /0113316 Al 6 / 2003 Kaisheva et al. Du and Klibanov , “ Hydrophobic salts markedly diminish viscosity 2004 /0191243 AL 9 / 2004 Chen et al. of concentrated protein solutions” , Biotechnol Bioeng . , 108 :632 - 6 2004 / 0197324 Al 10 / 2004 Liu et al. (2011 ) . 2005 /0158303 A1 7 / 2005 Liu et al. Guo , et al. , “ Structure - activity relationship for hydrophobic salts as 2006 /0142234 AL 6 / 2006 Chen et al. 2007 /0053900 A1 3 / 2007 Liu et al. viscosity - lowering excipients for concentrated solutions of mono 2008 /0071063 Al 3 / 2008 Allan et al. clonal antibodies ” , Pharm Res. , 29 : 3102 - 9 ( 2012 ) . 2008 / 0226689 Al 9 / 2008 Berry Jezek , et al. , “ Viscosity of concentrated therapeutic protein com 2009/ 0280129 Al 11 / 2009 Liu et al . positions” , Adv Drug Deliv Rev. , 63 : 1107 - 17 ( 2011 ) . 2010 /0061949 A1 3 / 2010 Schmidt- Jacobsen Miller , et al . , “ Low viscosity highly concentrated injectable 2010 /0239567 A1 9 / 2010 Esue nonaqueous suspensions of lysozyme microparticies” , Langmuir , 2011 /0145940 Al 6 / 2011 Voytas et al . 2011/ 0262626 Al 10 / 2011 Sun 26 : 1067 - 74 (2010 ) . 2011/ 0305734 Al 12 / 2011 Edelson et al . Shire , et al. , “ Challenges in the development of high protein 2012 /0230982 AL 9 / 2012 Zhou concentration formulations ” , J . Pharm . Sci. , 93 :1390 -1402 (2004 ) . 2012 /0231009 AL 9 / 2012 Ramani et al . Srinivasan , et al. , “ Non - aqueous suspensions of antibodies are much 2012 / 0263783 Al 10 / 2012 Messmer less viscous than equally concentrated aqueous solutions” , Pharm . 2013 / 0028907 AL 1 / 2013 Parshad et al . Res ., 30 : 1749 - 57 ( 2013 ) 2013 / 0028920 A 1 / 2013 Gurny Wang, et al ., “ Antibody structure, instability , and formulation ” , J . 2013 /0058958 Al 3 / 2013 Bowen et al. Pharm . Sci ., 96 : 1 - 26 ( 2007 ) . 2013 /0171128 A1 7 / 2013 Huang et al. 2013 / 0216525 AL 8 / 2013 Chen Hawe, et al. , Fluorescent molecular rotors as dyes to characterize 2013 /0309226 A1 11 / 2013 Armstrong et al . polysorbate -containing IgG formulations, Pharma Res . , 27 ( 2 ): 314 2014 / 0023655 Al 1 / 2014 Monck et al . 26 ( 2009 ) . 2014 /0127227 AL 5 / 2014 Chang Jacobson , et al ., “ 1 , 1 - Dicyano - 2 - [ 6 - (dimethylamino )naphthalen - 2 2014 / 0294859 Al 10 / 2014 Sloey et al.
Recommended publications
  • Recent Advances in Inflammatory Bowel Disease: Mucosal Immune

    Recent Advances in Inflammatory Bowel Disease: Mucosal Immune

    Recent advances in basic science Recent advances in inflammatory bowel disease: Gut: first published as 10.1136/gutjnl-2012-303955 on 8 October 2013. Downloaded from mucosal immune cells in intestinal inflammation M Zaeem Cader,1,2 Arthur Kaser1 1Department of Medicine, ABSTRACT Recent years have seen a rapid and exciting Division of Gastroenterology & The intestine and its immune system have evolved to expansion in our understanding of the mucosal Hepatology, University of Cambridge, Addenbrooke’s meet the extraordinary task of maintaining tolerance to immune system with novel insights into environ- Hospital, Cambridge, UK the largest, most complex and diverse microbial mental influences of diet and the microbiota; the 2Wellcome Trust PhD commensal habitat, while meticulously attacking and convergence and integration of fundamental cellu- Programme for Clinicians, containing even minute numbers of occasionally lar processes such as autophagy, microbial sensing Cambridge Institute for incoming pathogens. While our understanding is still far and endoplasmic reticulum (ER) stress; as well as Medical Research, School of Clinical Medicine, University of from complete, recent studies have provided exciting the discovery of new cell types, for example innate Cambridge, Cambridge, UK novel insights into the complex interplay of the many lymphoid cells (ILCs). distinct intestinal immune cell types as well as the The gut is unlike the systemic immune system in Correspondence to discovery of entirely new cell subsets. These studies have several respects and much of the extensive reper- Dr Arthur Kaser, Department of Medicine, Division of also revealed how proper development and function of toire of immune cells and their characteristics are Gastroenterology and the intestinal immune system is dependent on its specific indeed unique to the intestine.
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
  • The Role of Biological Therapy in Metastatic Colorectal Cancer After First-Line Treatment: a Meta-Analysis of Randomised Trials

    The Role of Biological Therapy in Metastatic Colorectal Cancer After First-Line Treatment: a Meta-Analysis of Randomised Trials

    REVIEW British Journal of Cancer (2014) 111, 1122–1131 | doi: 10.1038/bjc.2014.404 Keywords: colorectal; biological; meta-analysis The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials E Segelov1, D Chan*,2, J Shapiro3, T J Price4, C S Karapetis5, N C Tebbutt6 and N Pavlakis2 1St Vincent’s Clinical School, University of New South Wales, Sydney, NSW 2052, Australia; 2Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, Australia; 3Monash University and Cabrini Hospital, Melbourne, VIC 3800, Australia; 4The Queen Elizabeth Hospital and University of Adelaide, Woodville South, SA 5011, Australia; 5Flinders University and Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Bedford Park, SA, 5042, Australia and 6Austin Health, VIC 3084, Australia Purpose: Biologic agents have achieved variable results in relapsed metastatic colorectal cancer (mCRC). Systematic meta-analysis was undertaken to determine the efficacy of biological therapy. Methods: Major databases were searched for randomised studies of mCRC after first-line treatment comparing (1) standard treatment plus biologic agent with standard treatment or (2) standard treatment with biologic agent with the same treatment with different biologic agent(s). Data were extracted on study design, participants, interventions and outcomes. Study quality was assessed using the MERGE criteria. Comparable data were pooled for meta-analysis. Results: Twenty eligible studies with 8225 patients were identified. The use of any biologic therapy improved overall survival with hazard ratio (HR) 0.87 (95% confidence interval (CI) 0.82–0.91, Po0.00001), progression-free survival (PFS) with HR 0.71 (95% CI 0.67–0.74, Po0.0001) and overall response rate (ORR) with odds ratio (OR) 2.38 (95% CI 2.03–2.78, Po0.00001).
  • CNTO 888) Concentration Time Data

    CNTO 888) Concentration Time Data

    Pharmacokinetics and Pharmacodynamics The Journal of Clinical Pharmacology Utilizing Pharmacokinetics/Pharmacodynamics 53(10) 1020–1027 ©2013, The American College of Modeling to Simultaneously Examine Clinical Pharmacology DOI: 10.1002/jcph.140 Free CCL2, Total CCL2 and Carlumab (CNTO 888) Concentration Time Data Gerald J. Fetterly, PhD1, Urvi Aras, PhD1, Patricia D. Meholick, MS1, Chris Takimoto, MD, PhD2, Shobha Seetharam, PhD2, Thomas McIntosh, MS2, Johann S. de Bono, MD, PhD3, Shahneen K. Sandhu, MD3, Anthony Tolcher, MD4, Hugh M. Davis, PhD2, Honghui Zhou, PhD, FCP2, and Thomas A. Puchalski, PharmD2 Abstract The chemokine ligand 2 (CCL2) promotes angiogenesis, tumor proliferation, migration, and metastasis. Carlumab is a human IgG1k monoclonal antibody with high CCL2 binding affinity. Pharmacokinetic/pharmacodynamic data from 21 cancer patients with refractory tumors were analyzed. The PK/PD model characterized the temporal relationships between serum concentrations of carlumab, free CCL2, and the carlumab–CCL2 complex. Dose‐dependent increases in total CCL2 concentrations were observed and were consistent with shifting free CCL2. Free CCL2 declined rapidly after the initial carlumab infusion, returned to baseline within 7 days, and increased to levels greater than baseline following subsequent doses. Mean predicted half‐lives of carlumab and carlumab–CCL2 complex were approximately 2.4 days and approximately 1 hour for free CCL2. The mean dissociation constant (KD), 2.4 nM, was substantially higher than predicted by in vitro experiments,
  • Targeted and Novel Therapy in Advanced Gastric Cancer Julie H

    Targeted and Novel Therapy in Advanced Gastric Cancer Julie H

    Selim et al. Exp Hematol Oncol (2019) 8:25 https://doi.org/10.1186/s40164-019-0149-6 Experimental Hematology & Oncology REVIEW Open Access Targeted and novel therapy in advanced gastric cancer Julie H. Selim1 , Shagufta Shaheen2 , Wei‑Chun Sheu3 and Chung‑Tsen Hsueh4* Abstract The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of angiogenesis, human epidermal growth factor receptor 2 (HER2), mesenchymal–epithelial transition, epidermal growth factor receptor, mammalian target of rapamycin, claudin‑18.2, programmed death‑1 and DNA. Addition of trastuzumab to platinum‑ based chemotherapy has become standard of care as front‑line therapy in advanced GC overexpressing HER2. In the second‑line setting, ramucirumab with paclitaxel signifcantly improves overall survival compared to paclitaxel alone. For patients with refractory disease, apatinib, nivolumab, ramucirumab and TAS‑102 have demonstrated single‑agent activity with improved overall survival compared to placebo alone. Pembrolizumab has demonstrated more than 50% response rate in microsatellite instability‑high tumors, 15% response rate in tumors expressing programmed death ligand 1, and non‑inferior outcome in frst‑line treatment compared to chemotherapy. This review summarizes the current state and progress of research on targeted therapy for advanced GC. Keywords: Gastric cancer, Targeted therapy, Human epidermal growth factor receptor 2, Programmed death‑1, Vascular endothelial growth factor receptor 2 Background GC mortality which is consistent with overall decrease in Gastric cancer (GC), including adenocarcinoma of the GC-related deaths [4]. gastroesophageal junction (GEJ) and stomach, is the ffth Tere have been several eforts to perform large-scale most common cancer and the third leading cause of can- molecular profling and classifcation of GC.
  • Development of Red Blood Cell Autoantibodies Following Treatment with Checkpoint Inhibitors

    Development of Red Blood Cell Autoantibodies Following Treatment with Checkpoint Inhibitors

    CASE R EP O RT Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation L.L.W. Cooling, J. Sherbeck, J.C. Mowers, and S.L. Hugan Ipilimumab, nivolumab, and pembrolizumab represent a new Table 1. Checkpoint inhibitors class of immunotherapeutic drugs for treating patients with Drug class (trade name, manufacturer) advanced cancer. Known as checkpoint inhibitors, these drugs act to upregulate the cellular and humoral immune response Anti-CTLA-4 to tumor antigens by inhibiting T-cell autoregulation. As a Ipilimumab (Yervoy, Bristol-Myers Squibb) consequence, they can be associated with immune-related adverse Tremelimumab (AstraZeneca, compassionate use only) events (irAEs) due to loss of self-tolerance, including rare cases of immune-related cytopenias. We performed a retrospective Anti-PD-1 clinical chart review, including serologic, hematology, and Nivolumab (Opdivo, Bristol-Myers Squibb) chemistry laboratory results, of two patients who developed Pembrolizumab (Keytruda, Merck Sharp & Dohme) red blood cell (RBC) autoantibodies during treatment with a Pidilizumab (Medivations, in clinical trials) checkpoint inhibitor. Serologic testing of blood samples from these patients during induction therapy with ipilimumab and Anti-PD-L1 nivolumab, respectively, showed their RBCs to be positive by Atezolizumab (Genentech, in clinical trials) the direct antiglobulin test (IgG+, C3+) and their plasma to Durvalumab (AstraZeneca, approved bladder cancer) contain panreactive RBC autoantibodies. Neither patient had evidence of hemolysis. Both patients developed an additional CTLA-4 = cytotoxic T-lymphocyte–associated antigen 4; PD-1 = programmed cell death protein 1; PD-L1 = programmed cell death ligand 1.
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
  • Tanibirumab (CUI C3490677) Add to Cart

    Tanibirumab (CUI C3490677) Add to Cart

    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
  • The Future of Antibodies As Cancer Drugs

    The Future of Antibodies As Cancer Drugs

    REVIEWS Drug Discovery Today Volume 17, Numbers 17/18 September 2012 The biopharmaceutical industry’s pipeline of anticancer antibodies includes 165 candidates with substantial diversity in composition, targets and mechanisms of action that hold promise to be the cancer drugs of the future. Reviews FOUNDATION REVIEW Foundation review: The future of antibodies as cancer drugs 1 2 Dr Janice Reichert Janice M. Reichert and Eugen Dhimolea is Research Assistant Professor at Tufts 1 Center for the Study of Drug Development, Tufts University School of Medicine, 75 Kneeland Street, University’s Center for the Study of Drug Development Suite 1100, Boston, MA 02111, USA 2 (CSDD). She is also Founder Department of Medical Oncology, Dana-Farber Cancer Institute/Harvard Medical School, 77 Louis Pasteur Ave., and Editor-in-Chief of mAbs, Harvard Institutes of Medicine, Room 309, Boston, MA 02215, USA a peer-reviewed, PubMed- indexed biomedical journal that focuses on topics relevant to antibody research Targeted therapeutics such as monoclonal antibodies (mAbs) have proven and development; President of the board of directors of The Antibody Society; and a member of the board successful as cancer drugs. To profile products that could be marketed in of the Peptide Therapeutics Foundation. At CSDD, the future, we examined the current commercial clinical pipeline of mAb Dr Reichert studies innovation in the pharmaceutical and biotechnology industries. Her work focuses on candidates for cancer. Our analysis revealed trends toward development of strategic analyses of investigational candidates and marketed products, with an emphasis on the clinical a variety of noncanonical mAbs, including antibody–drug conjugates development and approval of new therapeutics and (ADCs), bispecific antibodies, engineered antibodies and antibody vaccines.
  • Ectrims Meeting November 2015

    Ectrims Meeting November 2015

    SUPPLEMENT TO HIGHLIGHTS FROM THE ECTRIMS MEETING NOVEMBER 2015 Ocrelizumab May Reduce Disability Progression in People With Primary Progressive MS Data support the hypothesis that B cells are central to the underlying biology of MS. BARCELONA—In people with primary progressive Overall, the incidence of adverse events associated multiple sclerosis (MS), treatment with ocrelizumab may with ocrelizumab was similar to that of placebo. The most significantly reduce the progression of clinical disability common adverse events were mild-to-moderate infusion- sustained for at least 12 weeks, compared with placebo, related reactions. The incidence of serious adverse events according to results from a pivotal phase III study presented associated with ocrelizumab, including serious infections, at the 31st Congress of the European Committee for Treat- was also similar to that of placebo. ment and Research in Multiple Sclerosis (ECTRIMS). In the “People with the primary progressive form of MS typi- study, which is called ORATORIO, clinical disability was cally experience symptoms that continuously worsen after measured by the Expanded Disability Status Scale (EDSS). the onset of their disease, and there are no approved treat- Ocrelizumab is an investigational, humanized mono- ments for this debilitating condition,” said Sandra Horn- clonal antibody designed to selectively target CD20-posi- ing, MD, Chief Medical Officer and Head of Global Product tive B cells. CD20-positive B cells are a type of immune cell Development for Genentech, the developer
  • Therapeutic Targeting of the IGF Axis

    Therapeutic Targeting of the IGF Axis

    cells Review Therapeutic Targeting of the IGF Axis Eliot Osher and Valentine M. Macaulay * Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK * Correspondence: [email protected]; Tel.: +44-1865617337 Received: 8 July 2019; Accepted: 9 August 2019; Published: 14 August 2019 Abstract: The insulin like growth factor (IGF) axis plays a fundamental role in normal growth and development, and when deregulated makes an important contribution to disease. Here, we review the functions mediated by ligand-induced IGF axis activation, and discuss the evidence for the involvement of IGF signaling in the pathogenesis of cancer, endocrine disorders including acromegaly, diabetes and thyroid eye disease, skin diseases such as acne and psoriasis, and the frailty that accompanies aging. We discuss the use of IGF axis inhibitors, focusing on the different approaches that have been taken to develop effective and tolerable ways to block this important signaling pathway. We outline the advantages and disadvantages of each approach, and discuss progress in evaluating these agents, including factors that contributed to the failure of many of these novel therapeutics in early phase cancer trials. Finally, we summarize grounds for cautious optimism for ongoing and future studies of IGF blockade in cancer and non-malignant disorders including thyroid eye disease and aging. Keywords: IGF; type 1 IGF receptor; IGF-1R; cancer; acromegaly; ophthalmopathy; IGF inhibitor 1. Introduction Insulin like growth factors (IGFs) are small (~7.5 kDa) ligands that play a critical role in many biological processes including proliferation and protection from apoptosis and normal somatic growth and development [1]. IGFs are members of a ligand family that includes insulin, a dipeptide comprised of A and B chains linked via two disulfide bonds, with a third disulfide linkage within the A chain.
  • (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies Et Al

    (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies Et Al

    US009 161992B2 (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies et al. (45) Date of Patent: Oct. 20, 2015 (54) P97 FRAGMENTS WITH TRANSFER 4,683.202 A 7, 1987 Mullis ACTIVITY 4,704,362 A 11/1987 Itakura et al. 4,766,075 A 8, 1988 Goeddeletal. (71) Applicant: biosis Technologies, Inc., Richmond 4,800,1594,784.950 A 11/19881/1989 MullisHagen et al. (CA) 4,801,542 A 1/1989 Murray et al. 4.866,042 A 9, 1989 Neuwelt (72) Inventors: Wilfred Jefferies, South Surrey (CA); 4,935,349 A 6/1990 McKnight et al. Mei Mei Tian, Coquitlam (CA): 4.946,778 A 8, 1990 Ladner et al. Timothy Vitalis, Vancouver (CA) 5,091,513 A 2f1992 Huston et al. 5,132,405 A 7, 1992 Huston et al. (73) Assignee: biOasis Technologies, Inc., British 5, 186,941 A 2f1993 Callahan et al. Columbia (CA) 5,672,683 A 9, 1997 Friden et al. 5,677,171 A 10, 1997 Hudziak et al. c - r 5,720,937 A 2f1998 Hudziak et al. (*) Notice: Subject to any disclaimer, the term of this 5,720,954. A 2f1998 Hudziak et al. patent is extended or adjusted under 35 5,725,856 A 3, 1998 Hudziak et al. U.S.C. 154(b) by 0 days. 5,770,195 A 6/1998 Hudziak et al. 5,772,997 A 6/1998 Hudziak et al. (21) Appl. No.: 14/226,506 5,844,093 A 12/1998 Kettleborough et al. 5,962,012 A 10, 1999 Lin et al.